当前位置：
X-MOL 学术
›
Hepatol. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real-world multicenter cohort study
Hepatology Research ( IF 4.2 ) Pub Date : 2024-02-01 , DOI: 10.1111/hepr.14021 Hyunjae Shin 1 , Seung Up Kim 2, 3 , Byeong Geun Song 4 , Youngsu Park 1 , Yunmi Ko 1 , Jeayeon Park 1 , Moon Haeng Hur 1 , Yun Bin Lee 1 , Eun Ju Cho 1 , Jeong‐Hoon Lee 1 , Su Jong Yu 1 , Jung‐Hwan Yoon 1 , Dong Hyun Sinn 4 , Yoon Jun Kim 1
Hepatology Research ( IF 4.2 ) Pub Date : 2024-02-01 , DOI: 10.1111/hepr.14021 Hyunjae Shin 1 , Seung Up Kim 2, 3 , Byeong Geun Song 4 , Youngsu Park 1 , Yunmi Ko 1 , Jeayeon Park 1 , Moon Haeng Hur 1 , Yun Bin Lee 1 , Eun Ju Cho 1 , Jeong‐Hoon Lee 1 , Su Jong Yu 1 , Jung‐Hwan Yoon 1 , Dong Hyun Sinn 4 , Yoon Jun Kim 1
Affiliation
|
Antiviral treatment reduces the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. However, there is a lack of high-quality evidence regarding the preventive effects of tenofovir alafenamide (TAF) on HCC. We evaluated the impact of TAF use after curative treatment on HCC recurrence.
中文翻译：
从富马酸替诺福韦二吡呋酯或恩替卡韦转为替诺福韦艾拉酚胺时，治愈性治疗后发生肝细胞癌的风险：一项真实世界多中心队列研究
抗病毒治疗可降低慢性乙型肝炎患者患肝细胞癌 (HCC) 的风险。然而，缺乏关于替诺福韦艾拉酚胺 (TAF) 对 HCC 预防作用的高质量证据。我们评估了治愈性治疗后使用 TAF 对 HCC 复发的影响。
更新日期：2024-02-01
中文翻译：
从富马酸替诺福韦二吡呋酯或恩替卡韦转为替诺福韦艾拉酚胺时，治愈性治疗后发生肝细胞癌的风险：一项真实世界多中心队列研究
抗病毒治疗可降低慢性乙型肝炎患者患肝细胞癌 (HCC) 的风险。然而，缺乏关于替诺福韦艾拉酚胺 (TAF) 对 HCC 预防作用的高质量证据。我们评估了治愈性治疗后使用 TAF 对 HCC 复发的影响。
京公网安备 11010802027423号